MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt Germany, has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 square feet of lab space and production capability to manufacture cell culture media.

Cell culture media is an essential raw material used in the manufacture of life-saving therapies and in processes as varied as vaccine manufacturing, gene therapy, and monoclonal antibody manufacturing. Because of its central role in biomanufacturing, a consistent supply of high-quality media is required to deliver the necessary concentration and protein quality for therapeutics.

The company's strategic investments to expand capacity with the new dry powder media manufacturing lines in existing production facilities in the Lenexa, Kansas, and Nantong, China, sites will increase both local and global production capacity to meet current demand and ensure supply for future demand surges, ensuring for future supply robustness.